DelveInsight’s, “CAR-T Therapy Pipeline Insight 2023” report provides comprehensive insights about 200+ companies and 252+ pipeline drugs in the CAR-T Therapy pipeline landscape. It covers the CAR-T Therapy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CAR-T Therapy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the CAR-T Therapy Pipeline Report

• DelveInsight’s CAR-T Therapy pipeline report depicts a robust space with 200+ active players working to develop 252+ pipeline therapies for CAR-T Therapy treatment.
• The leading companies working in the CAR-T Therapy Market include CARsgen, CASI Pharmaceuticals, Tessa Therapeutics, Cartesian Therapeutics, Gracell Bio, Aurora BioPharma, Carsgen Therapeutics, Autolus Limited, CRISPR Therapeutics, Allogene Therapeutics, Verismo Therapeutics, Arcellx, Nexcella, JW Therapeutics, Janssen Pharmaceuticals, Chongqing Precision Biotech, CoImmune Inc., Mustang Bio, Novartis Pharmaceuticals, Shanghai Unicar-Therapy Bio-medicine Technology, Sotio Biotech Inc., Beam Therapeutics, AbCLon, Nanjing IASO Biotherapeutics, Autolus, Beijing Immunochina Medical Science and Technology, Carsgen Therapeutics, Orgenesis, IN8Bio, Oxford BioMedica, and others.
• Promising CAR-T Therapy Pipeline Therapies in the various stages of development include Glofitamab, Obinutuzumab, Tocilizumab, Pembrolizumab, and others.
• November 2023: Nektar Therapeutics announced a study of Phase 2 & 3 clinical trials for NKTR-255 at 1.5 µg/kg. This study will evaluate the safety and efficacy of NKTR-255 following CD19-directed chimeric antigen (CAR)-T cell therapy in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL).
• November 2023: Hoffmann-La Roche announced a study of Phase 1 clinical trials for Glofitamab, Obinutuzumab, and Tocilizumab. The purpose of this study is to evaluate the preliminary efficacy, safety, and pharmacokinetics of glofitamab (glofit) in combination with rituximab plus ifosfamide, carboplatin, and etoposide (R-ICE) in participants with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have failed one prior line of therapy incorporating an anti-cluster of differentiation (CD) 20 antibody (i.e., rituximab) and an anthracycline, and who are transplant or chimeric antigen receptor T-cell (CAR-T) therapy eligible, defined as being medically eligible for intensive platinum-based salvage therapy followed by autologous stem cell transplantation (ASCT) or for CAR-T therapy.
• November 2023: Chongqing Precision Biotech Co., Ltd announced a study of Phase 1 clinical trials CEA CAR-T cells. This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CEA-positive advanced/metastatic solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.
• November 2023: Novartis Pharmaceuticals announced a study of Phase 2 clinical trials for PHE885. This is a Phase II study to determine the efficacy and safety of PHE885, a BCMA-directed CAR-T cell therapy, manufactured with a new process. The CAR-T cell therapy will be investigated as a single agent in relapsed and refractory multiple myeloma.
• November 2023: Janssen Research & Development LLC announced a study of Phase 3 clinical trials for Bortezomib, Dexamethasone, Lenalidomide and Cyclophosphamide. The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as initial therapy in terms of Progression Free Survival (PFS).

 

Request a sample and discover the recent advances in CAR-T Therapy Treatment Drugs @ CAR-T Therapy Pipeline Report

 

In the CAR-T Therapy Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, CAR-T Therapy NDA approvals (if any), and product development activities comprising the technology, CAR-T Therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

CAR-T Overview

Chimeric Antigen Receptors (CARs), also known as chimeric immunoreceptors, chimeric T cell receptors or artificial T cell receptors—are receptor proteins that have been engineered to give T cells the new ability to target a specific antigen. The receptors are chimeric in that they combine both antigen-binding and T cell activating functions into a single receptor.

 

Find out more about CAR-T Therapy Therapeutics Assessment @ CAR-T Therapy Preclinical and Discovery Stage Products

 

CAR-T Therapy Emerging Drugs Profile

• CT053: Carsgen Therapeutics
• Descartes-08: Cartesian Therapeutics
• ALLO-501A: Allogene Therapeutics
• CTX110: CRISPR Therapeutics
• IMPT 314: ImmPACT Bio
• ALLO-715: Allogene Therapeutics

 

CAR-T Pipeline Therapeutics Assessment

There are approx. 200+ key companies which are developing the CAR-T Therapy therapies. The CAR-T Therapy companies which have their CAR-T Therapy drug candidates in the most advanced stage, i.e. Registered include, Carsgen Therapeutics.

 

DelveInsight’s CAR-T Therapy Pipeline Report covers around 252+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

CAR-T Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

CAR-T Therapy Pipeline Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Learn more about the emerging CAR-T Therapy Pipeline Therapies @ CAR-T Therapy Clinical Trials Assessment

 

Scope of the CAR-T Therapy Pipeline Report

• Coverage- Global
• CAR-T Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• CAR-T Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• CAR-T Therapy Companies- CARsgen, CASI Pharmaceuticals, Tessa Therapeutics, Cartesian Therapeutics, Gracell Bio, Aurora BioPharma, Carsgen Therapeutics, Autolus Limited, CRISPR Therapeutics, Allogene Therapeutics, Verismo Therapeutics, Arcellx, Nexcella, JW Therapeutics, Janssen Pharmaceuticals, Chongqing Precision Biotech, CoImmune Inc., Mustang Bio, Novartis Pharmaceuticals, Shanghai Unicar-Therapy Bio-medicine Technology, Sotio Biotech Inc., Beam Therapeutics, AbCLon, Nanjing IASO Biotherapeutics, Autolus, Beijing Immunochina Medical Science and Technology, Carsgen Therapeutics, Orgenesis, IN8Bio, Oxford BioMedica, and others.
• CAR-T Therapy Pipeline Therapies- Glofitamab, Obinutuzumab, Tocilizumab, Pembrolizumab, and others.

 

Dive deep into rich insights for new drugs for CAR-T Therapy Treatment, Visit @ CAR-T Therapy Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. CAR-T Therapy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. CAR-T Therapy– DelveInsight’s Analytical Perspective
7. Late Stage Products (Registered)
8. CT053: Carsgen Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Descartes-08: Cartesian Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ALLO-715: Allogene Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. ACLX 003: Arcellx
18. Drug profiles in the detailed report…..
19. Inactive Products
20. CAR-T Therapy Key Companies
21. CAR-T Therapy Key Products
22. CAR-T Therapy- Unmet Needs
23. CAR-T Therapy- Market Drivers and Barriers
24. CAR-T Therapy- Future Perspectives and Conclusion
25. CAR-T Therapy Analyst Views
26. CAR-T Therapy Key Companies
27. Appendix

 

For further information on the CAR-T Therapy Pipeline therapeutics, reach out to CAR-T Therapy Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting